Odyssey Therapeutics, a biotech firm focused on autoimmune diseases, debuted on the Nasdaq with shares rising 11.1%, leading to a valuation of $899.9 million. The Boston-based company raised $279 million by selling 15.5 million shares at the top end of its price range. This successful IPO is a positive sign for the biotech sector, which has seen a resurgence in investor interest following a lackluster 2025. The company's treatment OD-001 is currently in mid-stage trials for ulcerative colitis. Founded in 2021 by Dr. Gary D. Glick, who previously led Scorpion Therapeutics to a lucrative acquisition by Eli Lilly, Odyssey's strong debut reflects growing confidence in the biotech market. Analysts suggest that this trend may encourage more biotech firms to pursue public offerings as investor appetite returns.